Revelation Biosciences (REVB) AI Stock Analysis

• Market Cap: $2.98M
• Dividend Yield: N/A
• Average Volume (3M): 740.56K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.50
• Revenue Growth: N/A
• EPS Growth: 96.26%
• Country: US
• Employees: 8
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -7.08
• Shares Outstanding: 1,583,951
• 10 Day Avg. Volume: 239,834
• 30 Day Avg. Volume: 740,557
• PEG Ratio: >-0.01
• Price to Book (P/B): 0.81
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.21
• Enterprise Value/Market Cap: -3.44
• Enterprise Value/Revenue: -379.59
• Enterprise Value/Gross Profit: -759.17
• Enterprise Value/Ebitda: 1.25
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 45 Neutral
• Price Target: $1.50 ▲(66.67% Upside)

The score is held down primarily by weak financials (no revenue, ongoing losses, and significant cash burn implying future funding needs) and a clearly bearish technical trend (below major moving averages with negative MACD). Offsetting factors include a relatively stronger, debt-free balance sheet and positive corporate developments, including new capital raised and clinical/program progress.

Positive Factors

Debt-free balance sheet

A debt-free capital structure materially lowers financial risk for a clinical-stage biotech. With no interest burden, the company retains flexibility to allocate capital to R&D and regulatory work, improving survivability through multi-phase clinical programs and reducing default risk.

Near-term liquidity from warrant inducement

The $7.3M raised via warrant inducement provides tangible runway to advance clinical plans and GMP activities. This non-revenue cash infusion reduces immediate financing pressure, allowing program milestones and regulatory interactions to proceed without an immediate dilutive public raise.

Clinical progress and FDA engagement

Completing Phase 1b and agreeing a regulatory pathway with the FDA are durable value drivers: they de-risk development, enable clearer development plans toward Phase 2/3, and increase the asset's strategic optionality for partnerships or licensing ahead of commercialization.

Negative Factors

No revenue and persistent losses

Lack of revenue and sustained net losses mean the business cannot self-fund development. Over the medium term this structural reliance on external capital increases execution risk, potential dilution, and puts pressure on management to secure financing before key milestones.

Significant negative cash flow and burn

Material negative operating and free cash flow that is worsening creates a persistent funding gap. This structural cash burn necessitates repeated financing rounds, limiting strategic flexibility, increasing dilution over time, and elevating risk if capital markets tighten.

Warrant overhang and dilution risk

The inducement deal issues new multi-year warrants and extends expirations, creating prolonged potential equity dilution and overhang. This structural cap table pressure can impair future financing terms, complicate valuation negotiations, and reduce per-share upside for existing holders.

Revelation Biosciences Business Overview & Revenue Model

Company Description

Revelation Biosciences, Inc. operates as a clinical-stage biopharmaceutical company that focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was formerly known as Petra Acquisition, Inc. and changed its name to Revelation Biosciences, Inc. in January 2022. Revelation Biosciences, Inc. was incorporated in 2019 and is based in San Diego, California.

How the Company Makes Money

Revelation Biosciences generates revenue primarily through the development and commercialization of its therapeutic candidates. The company's revenue model may include research and development collaborations, licensing agreements, and potential future product sales. Key revenue streams likely involve partnerships with larger pharmaceutical companies for joint development or commercialization efforts, as well as securing funding through grants or investments to support ongoing research. Currently, as a clinical-stage company, significant earnings may not be realized until products receive regulatory approval and reach the market.

Revelation Biosciences Financial Statement Overview

Summary

Income statement is very weak with no revenue and persistent losses (TTM net income about -$8.1M). Balance sheet is a relative strength (debt-free and equity improved to about $11.0M), but cash flow remains a major risk with deeply negative free cash flow (about -$10.0M TTM) and ongoing burn implying continued funding/dilution needs.

Income Statement

REVB continues to generate no revenue across the periods provided, while losses remain large. In TTM (Trailing-Twelve-Months), net income is about -$8.1M (improving versus the 2024 annual loss of about -$15.0M), but profitability remains deeply negative with meaningfully negative operating results. The main strength is the reduced loss level versus 2024, but the lack of revenue and persistent operating losses keep the income statement very weak.

Balance Sheet

The balance sheet is helped by a debt-free capital structure in the more recent periods (total debt is $0 in 2022–TTM), which lowers financial risk. Stockholders’ equity improved to about $11.0M in TTM from $4.7M in 2024, signaling better capitalization. However, returns on equity are strongly negative in recent years due to ongoing losses, and equity was negative in 2021, highlighting dilution/financing dependence and business-model risk despite low leverage.

Cash Flow

Cash burn is substantial and worsening versus the prior year: operating cash flow is about -$10.1M in TTM (Trailing-Twelve-Months) versus about -$18.3M in 2024, but free cash flow remains deeply negative at roughly -$10.0M in TTM, with free cash flow growth of -43.4% (a deterioration). Free cash flow is roughly in line with net losses (close to 1x), indicating losses are largely cash-based rather than purely accounting-driven—this transparency is a modest positive, but the magnitude of ongoing burn is a key weakness.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	26.96K	0.00	0.00	0.00	0.00	0.00
Gross Profit	13.48K	0.00	0.00	0.00	0.00	0.00
EBITDA	-8.19M	-7.95M	-8.63M	-10.84M	-11.93M	0.00
Net Income	-8.13M	-15.04M	-120.25K	-10.83M	-11.99M	-1.63M
Balance Sheet
Total Assets	12.86M	6.62M	12.21M	5.50M	2.04M	4.62M
Cash, Cash Equivalents and Short-Term Investments	12.71M	6.50M	11.99M	5.25M	1.27M	4.49M
Total Debt	0.00	0.00	0.00	0.00	16.75K	0.00
Total Liabilities	1.85M	1.91M	5.56M	4.45M	2.14M	1.21M
Stockholders Equity	11.00M	4.71M	6.65M	1.05M	-99.47K	3.41M
Cash Flow
Free Cash Flow	-10.03M	-18.34M	-7.29M	-11.22M	-11.22M	-215.07K
Operating Cash Flow	-10.05M	-18.32M	-7.29M	-11.22M	-11.09M	-215.07K
Investing Cash Flow	17.69K	-19.17K	0.00	0.00	-131.96K	-74.04M
Financing Cash Flow	16.20M	12.85M	14.03M	15.20M	8.00M	74.26M

Revelation Biosciences Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.90
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For REVB, the sentiment is Negative. The current price of 0.9 is below the 20-day moving average (MA) of 2.98, below the 50-day MA of 3.42, and below the 200-day MA of 10.78, indicating a bearish trend. The MACD of -0.50 indicates Positive momentum. The RSI at 20.47 is Positive, neither overbought nor oversold. The STOCH value of 3.37 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for REVB.

Revelation Biosciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
DRMA	47 Neutral	$5.73M	-0.09	-203.36%	―	―	90.53%
REVB	45 Neutral	$2.98M	-0.01	-118.88%	―	―	96.26%
AZTR	45 Neutral	$2.63M	-0.04	-215.04%	―	-100.00%	93.82%
GTBP	40 Underperform	$5.43M	-0.15	-356.99%	―	―	54.62%

Revelation Biosciences Corporate Events

Revelation Biosciences Raises Capital via Warrant Inducement

On January 23, 2026, Revelation Biosciences entered into inducement agreements with two holders of its existing Class I common stock warrants, leading to the immediate cash exercise of 8,544,999 pre-split (2,136,251 post-split) warrants at an effective post-split price of $3.44 per share, generating approximately $7.3 million in gross proceeds to support its clinical development plans, working capital and general corporate needs. In return, the company issued 17,089,998 pre-split (4,272,500 post-split) new Class J common stock warrants in a private placement exempt from registration, with the new warrants becoming exercisable for five years following stockholder approval, while Revelation agreed to file a resale registration statement for the underlying shares and pay Roth Capital Partners an 8% advisory fee; the company also clarified that an initially expected third investor ultimately withdrew, reducing the originally anticipated size of the transaction.

The most recent analyst rating on (REVB) stock is a Hold with a $0.51 price target. To see the full list of analyst forecasts on Revelation Biosciences stock, see the REVB Stock Forecast page.

Revelation Biosciences Extends Stock Warrants Expiration

On December 3, 2025, Revelation Biosciences held a Special Meeting where stockholders approved the issuance of shares related to Class I Common Stock Warrants, extending their expiration to December 3, 2030. The company also provided a corporate update, highlighting the completion of a Phase 1b clinical study for Gemini in CKD patients, showcasing promising results in inflammation treatment. As they prepare for a meeting with the FDA, Revelation Biosciences plans to advance Gemini’s development for acute kidney injury treatment, aiming to start a Phase 2 or Phase 3 clinical study in 2026.

The most recent analyst rating on (REVB) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Revelation Biosciences stock, see the REVB Stock Forecast page.